HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of 5-episisomicin (Sch 22591), gentamicin, sisomicin, and tobramycin in treatment of experimental Pseudomonas infections in mice.

Abstract
Sch 22591 (5-episisomicin), gentamicin, sisomicin, and tobramycin were compared for their ability to protect mice from lethal intraperitoneal challenge with 12 Pseudomonas strains, all susceptible to each of the aminoglycosides (minimal inhibitory concentrations and minimal bactericidal concentrations were </=6.2 mug/ml). Median 50% protective doses were 5.8, 6.4, 7.7, and 17.8 mg/kg for Sch 22591, tobramycin, sisomicin, and gentamicin, respectively. Those for Sch 22591 were significantly lower than gentamicin in five protection tests and significantly lower than both gentamicin and tobramycin in one test. Microbial analysis of the therapeutic effect indicated that protection from lethality by each of the four aminoglycosides was associated with either a complete eradication or a reduction in the number of challenge bacteria in both the heart blood and peritoneum. In rare instances, challenge isolates exhibiting decreased susceptibility to one or more of the aminoglycosides were recovered from animals. However, this in vivo selection of resistance did not appear related to either the aminoglycoside used in therapy or the outcome of therapy, and resistant isolates were recovered as frequently from untreated animals as from those receiving one of the four aminoglycosides.
AuthorsR V Goering, C C Sanders, W E Sanders Jr
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 14 Issue 6 Pg. 824-8 (Dec 1978) ISSN: 0066-4804 [Print] United States
PMID742870 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Gentamicins
  • Tobramycin
  • Sisomicin
Topics
  • Animals
  • Anti-Bacterial Agents (therapeutic use)
  • Drug Evaluation
  • Gentamicins (therapeutic use)
  • Lethal Dose 50
  • Mice
  • Pseudomonas Infections (drug therapy)
  • Sisomicin (therapeutic use)
  • Stereoisomerism
  • Tobramycin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: